Compass Pathways

Recent advancements in understanding mental health and the brain have allowed us to identify possible commonalities between different mental health conditions. One of the shared experiences among patients with conditions like treatment-resistant depression (TRD), bipolar II disorder and PTSD is the...

Artificial Intelligence (AI) is rapidly penetrating a number of different sectors, including healthcare. The use of AI in mental health has opened up the possibility of new avenues of care, potentially allowing for more efficient diagnosis, treatment and patient care. Machine learning algorithms...

Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by persistent symptoms of depression that do not respond adequately to at least two different standard...

In August, a group of well-known biotech institutional investors participated in an up to almost $300 million financing round for COMPASS Pathways (NASDAQ: CMPS), consisting of an initial investment of $125 million and the potential for an additional investment of up to $160 million if the...

Patents are the golden eggs of the booming psychedelic space. In an industry that revolves around substances that are found in nature (such as psilocybin, ibogaine or DMT) or compounds whose patents have already expired (LSD and MDMA), new patents are the primary way in which companies can ...

Compass Pathways plc (NASDAQ:CMPS) and California-based non-profit organization One Mind partnered to sponsor three “2022 One Mind - COMPASS Rising Stars Awards.” Since 2005, the One Mind Rising Star Awards aim to fund research on novel studies on brain health conditions. This year,...

atai Life Sciences N.V. (NASDAQ: ATAI) has announced its financial results for the fourth quarter and full year ended December 31, 2021. 2021 Financial Results Highlights included:  Positive Phase 2b data with COMP360 from a ground-breaking treatment-resistant depression (TRD) trial, highly...

As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher dose of 25mg (compared to 1mg and 10mg) occasioned an increase in positive feelings of interest in life and a decrease in...

Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ: ATAI), a Peter Thiel-backed psychedelic startup that currently has 10 psychedelic programs in the works, has upped its stake in Compass Pathways (NASDAQ: CMPS), a drug developer looking to accelerate patient access to psilocybin...

The state of Pennsylvania is poised to become a leader in psychedelic research after a bill known as the Public Health Benefits of Psilocybin Act was introduced recently in the House of Representatives. The proposed legislation looks to create a framework for clinical studies of psilocybin,...